Form 4: Veracyte Executive Sells Shares Under 10b5-1 Plan

Phillip G. Febbo, Chief Scientific & Medical Officer of Veracyte, Inc., sold 3,934 shares of common stock at an average price of $44.0893 per share.

Summary

• Phillip G. Febbo, the Chief Scientific & Medical Officer of Veracyte, Inc., sold 3,934 shares of the company's common stock on December 4, 2024.
• The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on September 4, 2024.
• The shares were sold at a weighted average price of $44.0893, with individual sale prices ranging from $43.60 to $44.46.
• Following the transaction, Mr. Febbo directly owns 82,414 shares of Veracyte common stock.

Sentiment

Score: 5

Explanation: The document reflects a routine stock sale by an executive under a pre-arranged plan. It is neither particularly positive nor negative.

Risks

• Executive stock sales can sometimes be perceived negatively by the market, potentially leading to short-term price fluctuations.

Industry Context

Executive stock sales are a common occurrence and are often part of pre-planned strategies for personal financial management. The use of a 10b5-1 plan indicates that the sales were pre-arranged and not based on any material non-public information.

Comparison to Industry Standards

• Rule 10b5-1 plans are a standard practice for corporate executives to sell shares without being accused of insider trading.
• The sale of 3,934 shares is relatively small compared to the total outstanding shares of Veracyte, and is not unusual for an executive's planned sales.

Stakeholder Impact

• The stock sale may have a minor impact on the share price, but it is unlikely to have a significant long-term effect on stakeholders.

Key Dates

Keywords

Veracyte, stock sale, insider trading, Form 4, Rule 10b5-1, executive, Phillip G. Febbo, VCYT